Adamas reports positive phase 1a data of ADS-4101 (lacosamide)
Adamas announced positive data from the Phase 1a clinical trial of ADS-4101 (lacosamide) modified-release capsules. ADS-4101 is in development for treatment of partial onset seizures in patients with epilepsy. This Phase 1a study showed improved tolerability versus the equivalent dose of VIMPAT®. May 22, 2017